Angiotensin-(1-7)

Phase 1Small molecule

UUniversity of Arizona

Angiotensin-(1-7) is one of 98 small molecule programs targeting Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionTerminated

Traumatic Brain InjuryRecruiting

CardiovascularRecruiting

ObesityActive, not recruiting

HypertensionPhase 1

Terminated

Traumatic Brain InjuryPreclinical

Recruiting

CardiovascularPhase 1

Recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 2

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 3

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

4 4

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 5

Eloralintide

Eli Lilly

Phase 3

10 6

Belantamab Mafodotin-Blmf

Novo Nordisk

Phase 3

1 7

Avapro

Sanofi

Preclinical

1 8

Amidate

Calciferol

Adenocard

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Cardiovascular

NCT05301192

Phase 1Active, not recruiting

Obesity

NCT03777215

Q3 2027

PreclinicalRecruiting

Traumatic Brain Injury

NCT06282965

Q1 2029

Phase 1Recruiting

Hypertension

NCT06482853

Q4 2029

Phase 1Recruiting

Study completion

NCT02646475

Clinical

Trials by Indication[1]

COVID-194 trials

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

Withdrawn·SStanford University·Phase 1/2·NCT04570501

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

Unknown status·EErasme University Hospital·Phase 2/3·NCT04332666·60 enrolled

Use of Angiotensin-(1-7) in COVID-19

Completed·EErasme University Hospital·Phase 1/2·NCT04633772·112 enrolled

Show 1 more trial

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

Unknown status·RRambam Health Care Campus·Phase 2·NCT04605887·120 enrolled

Hypertension2 trials

Angiotensin 1-7 in Obesity Hypertension

Terminated·AAmy Arnold·Phase 1·NCT03604289·8 enrolled

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Recruiting·MMilton S. Hershey Medical Center·Phase 1·NCT06482853·52 enrolled

Heart Failure2 trials

Biomarker Study: Heart Failure Patients at Risk

Unknown status·UUniversity of Arizona·Phase 1/2·NCT05336175·40 enrolled

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

Suspended·UUniversity of Arizona·Phase 2·NCT03159988·6 enrolled

Essential Hypertension1 trial

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Terminated·VVanderbilt University·Phase 1·NCT02245230·24 enrolled

Autonomic Failure1 trial

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Terminated·VVanderbilt University Medical Center·Phase 1·NCT02591173·7 enrolled

8 more indications

ART1 trial

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

Terminated·UUS Biotest, Inc.·Phase 1·NCT00757250·13 enrolled

Cardiovascular1 trial

Angiotensin-(1-7) Cardiovascular Effects in Aging

Recruiting·MMilton S. Hershey Medical Center·Phase 1·NCT05301192·26 enrolled

Obesity1 trial

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Active, not recruiting·AAmy Arnold·Phase 1·NCT03777215·30 enrolled

Hypertensive1 trial

Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects

Unknown status·IInstituto de Cardiologia do Rio Grande do Sul·Phase 1·NCT03001271·32 enrolled

Peripheral Arterial Disease1 trial

Angiotensin-(1-7) in Peripheral Arterial Disease

Terminated·MMilton S. Hershey Medical Center·Phase 1·NCT03240068·6 enrolled

Safety and Efficacy1 trial

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

Terminated·UUniversity of Arizona·Phase 2·NCT03252093·6 enrolled

Traumatic Brain Injury1 trial

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

Recruiting·UUniversity of Arizona·Preclinical·NCT06282965·90 enrolled

Unspecified1 trial

Metabolic Effects of Angiotensin-(1-7)

Recruiting·VVanderbilt University·Phase 1·NCT02646475·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Angiotensin-(1-7). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Angiotensin-(1-7) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Angiotensin-(1-7). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Arizona

Angiotensin-(1-7)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q1 2029

Q4 2029

Trials by Indication[1]

COVID-194 trials

Hypertension2 trials

Heart Failure2 trials

Essential Hypertension1 trial

Autonomic Failure1 trial

ART1 trial

Cardiovascular1 trial

Obesity1 trial

Hypertensive1 trial

Peripheral Arterial Disease1 trial

Safety and Efficacy1 trial

Traumatic Brain Injury1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News